ArticlePLoS genetics2019
Quantifying immune-based counterselection of somatic mutations.
Article in PLoS genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- A Strategy Utilizing Protein-Protein Interaction Hubs for the Treatment of Cancer Diseases.International journal of molecular sciences · 2023Review
- The Prognostic Significance of Selected HLA Alleles on Prostate Cancer Outcome.International journal of molecular sciences · 2023Article
- Comprehensive analysis of neoantigens derived from structural variation across whole genomes from 2528 tumors.Genome biology · 2023Article
- Autoimmune alleles at the major histocompatibility locus modify melanoma susceptibility.American journal of human genetics · 2023Article
- No evidence that HLA genotype influences the driver mutations that occur in cancer patients.Cancer immunology, immunotherapy : CII · 2022Article
- mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model.Frontiers in immunology · 2022Article
- Neoantigen Controversies.Annual review of biomedical data science · 2021Review
- Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting.Cell reports. Medicine · 2021Article
- Influence of T Cell-Mediated Immune Surveillance on Somatic Mutation Occurrences in Melanoma.Frontiers in immunology · 2021Article
- Identification of Somatic Mutation-Driven Immune Cells by Integrating Genomic and Transcriptome Data.Frontiers in cell and developmental biology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
Somatic mutations in protein-coding regions can generate 'neoantigens' causing developing cancers to be eliminated by the immune system. Quantitative estimates of the strength of this counterselection phenomenon have been lacking. We quantified the extent to which somatic mutations are depleted in peptides that are predicted to be displayed by major histocompatibility complex (MHC) class I proteins. The extent of this depletion depended on expression level of the neoantigenic gene, and on whether the patient had one or two MHC-encoding alleles that can display the peptide, suggesting MHC-encoding alleles are incompletely dominant. This study provides an initial quantitative understanding of counter-selection of identifiable subclasses of neoantigenic somatic variation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.